ICUI Stock Forecast: ICU Medical, Inc. Price Predictions for 2026-2027
The 7 Wall Street analysts covering ICU Medical, Inc. hold a median 12-month price target of $195 — +13.0% from the last close. Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 95 of 100 as at 21 Nov 2026 — among the strongest tenth. Here, the model and the Street point the same way.
One number for the whole business
Consensus tells you what everyone already believes. The model scores ICU Medical, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Value (93): The shares cost little relative to the profits and assets behind them — which can mean the market is too gloomy, or that the business really is in trouble.
Growth (58): Sales and profits are flat, shrinking, or growing more slowly than they were.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
ICUI stock forecast 2026-2027: analyst price targets & predictions
The bullish and bearish analyst opinions on ICUI, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +13.0% from it.
Of the 20 most recent actions, 6 moved their price target up and 0 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 6 Nov 2026 | Keybanc | Maintains | Overweight | $187 → $189 |
| 6 Nov 2026 | Piper Sandler | Maintains | Overweight | $195 → $200 |
| 7 Aug 2026 | BTIG | Maintains | Buy | $170 → $200 |
| 7 Aug 2026 | Keybanc | Maintains | Overweight | — |
| 7 Aug 2026 | Needham | Maintains | Buy | $165 → $187 |
| 7 Aug 2026 | Piper Sandler | Maintains | Overweight | $163 → $195 |
| 21 July 2026 | Keybanc | Maintains | Overweight | $164 → $182 |
| 15 June 2026 | BTIG | Initiates | Buy | $170 |
| 27 May 2026 | Needham | Upgrade | Buy | — |
| 27 Apr 2026 | Keybanc | Maintains | Overweight | — |
| 17 Apr 2026 | Piper Sandler | Maintains | Overweight | — |
| 20 Feb 2026 | Keybanc | Maintains | Overweight | — |
| 20 Feb 2026 | Piper Sandler | Maintains | Overweight | — |
| 7 Nov 2025 | Keybanc | Maintains | Overweight | — |
| 7 Nov 2025 | Piper Sandler | Maintains | Overweight | — |
| 21 Oct 2025 | Keybanc | Maintains | Overweight | — |
| 10 Sept 2025 | Piper Sandler | Maintains | Overweight | — |
| 15 Aug 2025 | Piper Sandler | Initiates | Overweight | — |
| 8 Aug 2025 | Raymond James | Maintains | Strong Buy | — |
| 9 May 2025 | Raymond James | Maintains | Strong Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Wall Street targets run 12 to 18 months out. No analyst publishes a 2030 price target for ICUI.
This page is one stock. Monday covers all of them.
ICUI appears in the Radar on the weeks it earns a place.
- Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
- The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and servers
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
ICUI vs the S&P 500
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 20 Nov 2026, ICU Medical, Inc. returned +28.4% against +6.9% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
ICUI analyst estimate revisions
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
Financials
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
- Trailing P/E
- 72.2×
- Price / sales
- 2.0×
- Price / book
- 2.0×
- EV / EBITDA
- 15.1×
Cheaper than 11% of US stocks
Cheaper than 49% of US stocks
Cheaper than 44% of US stocks
Cheaper than 34% of US stocks
- Revenue growth (YoY)
- 4.4%
- Earnings growth (YoY)
- —
- Gross margin
- 42.6%
- Operating margin
- 6.7%
- Net margin
- 2.8%
Higher than 39% of US stocks
Higher than 53% of US stocks
Higher than 57% of US stocks
Higher than 51% of US stocks
- Return on equity
- 2.8%
- Return on assets
- 2.3%
- Dividend yield
- —
Higher than 48% of US stocks
Higher than 59% of US stocks
Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.
Key statistics
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
ICU Medical, Inc. has a market value of $4.3B and an enterprise value of $5.2B.
Revenue in the twelve months to 30 June 2026: $2.2B. The latest quarter grew 0.5% year on year.
Net income over the same four quarters: $30.1M, a 1.4% net margin.
Diluted earnings per share, trailing twelve months: $1.18.
Free cash flow in the twelve months to 30 June 2026: $144.8M.
Trailing P/E: 72.2×; forward P/E: 17.8× — the forward figure prices analyst consensus estimates, not reported earnings.
ICU Medical, Inc. employs 13,000 people — $166K of revenue per employee.
Data provided by Twelve Data
ICUI and its peers
The nearest names by industry and size, scored by the same model — like for like.
Take a look at ICUI’s peer groups, ranked by the model: healthcare stocks.
Look up any of the roughly 4,300 stocks we score.
The rank is the raw material. Whether the rules would actually own ICU Medical, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Questions about ICUI
What is the ICUI stock price forecast for 2026-2027?
The 7 Wall Street analysts covering ICU Medical, Inc. have a median 12-month price target of $195, with estimates ranging from $178 to $210. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Is ICUI stock a buy right now?
Of the 7 analysts covering ICU Medical, Inc., 6 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks ICU Medical, Inc. 95 out of 100 across roughly 4,300 US stocks as at 21 Nov 2026. None of this is personal advice — it does not consider your circumstances.
How does Ticker Nerd's model rank ICUI?
As at 21 Nov 2026, ICU Medical, Inc. ranks 95 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Value (93 of 100).
Will ICUI stock go up?
No one can know that. What the data says: the median 12-month target from 7 analysts implies +13.0% from the last close, and Ticker Nerd's factor model ranks ICU Medical, Inc. 95 out of 100 as at 21 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
What is the ICUI stock forecast for 2030?
No analyst covering ICU Medical, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for ICUI are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $178 to $210 over the next 12 months.
How has ICUI stock performed over the past year?
ICU Medical, Inc. returned +28.4% over the 12 months to 20 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.
What does ICU Medical, Inc. do?
ICU Medical, Inc. is a medical technology company focused on infusion therapy, vascular access, and vital care products. ICU Medical develops, manufactures, and sells a broad portfolio that includes IV pumps, needlefree connectors, IV administration sets, sterile IV solutions, closed-system transfer devices for hazardous drugs, and safety software used in hospital and alternate care settings.
About ICU Medical, Inc.
ICU Medical, Inc. is a medical technology company focused on infusion therapy, vascular access, and vital care products. ICU Medical develops, manufactures, and sells a broad portfolio that includes IV pumps, needlefree connectors, IV administration sets, sterile IV solutions, closed-system transfer devices for hazardous drugs, and safety software used in hospital and alternate care settings. The company also offers hemodynamic monitoring, respiratory, anesthesia, temperature management, and other critical care products that support clinical workflows and patient safety. Its product families are designed to help healthcare providers deliver medications and fluids, reduce contamination risks, and improve efficiency across the IV continuum of care. ICU Medical serves acute care hospitals, ambulatory clinics, and home or alternate-site care environments, making it an important supplier in medical devices and hospital infrastructure.
CEO Mr. Vivek Jain · 13,000 employees · United States · https://www.icumed.com